Through its acquisition of d3 Medicine, Certara has expanded its Strategic Consulting (CSC) division, which uses a range of methods to support drug development.
Shire says it will appeal a decision invalidating a patent surrounding the controlled-release composition of its ulcerative colitis drug Lialda (mesalazine).
Since 2011, Samsung Biologics has built two plants, gained Bristol-Myers Squibb and Roche as clients and launched an IPO. With a third facility under construction, Biopharma-Reporter visited to see the CMO’s ambition in action.
Lonza has licensed rights to synthetic adeno-associated viral (AAV) vectors developed by scientists at US hearing research centre, Massachusetts Eye and Ear.
Aptar Pharma has formed an alliance with Becton, Dickinson & Co to develop new self-injection devices that will tap into the strong growth in injectable drugs.
Gerresheimer has agreed to sell its lab glassware business to a private equity investor, describing the deal as part of an effort to focus on delivery devices and pharmaceutical packaging.
Through their strategic commercial partnership, Medidata and SHYFT Analytics are aiming to increase access to healthcare data analytics in clinical trials.
The latest in a series of investments, Cambrex has recently expanded its Sweden-based site as part of its ongoing investment in small molecule API manufacturing across its global network of facilities.
The open-source study was launched in order to advance understanding of real-world experience with therapies and clinical outcomes in patients with multiple myeloma.
Capsugel plans to up micronisation capacity at Quakertown, Pennsylvania facility to provide API processing services for clinical candidates and commercial drugs.
The global excipient certification organization has announced IPEC Association (China) Limited as its fifth member, joining IPEC Europe, IPEC Americas, FECC, and PQG (UK).
Pharmaceutical Product Development, LLC (PPD), has announced the completed acquisition of Evidera as the two companies commit to making the “seamless offering a reality.”
A synthetic short cut could make it easier and cheaper to produce nitrile-containing compounds, a group which includes dozens of marketed and pipeline drugs.
According to a recent study, traditional efficacy trials have limited applicability in everyday clinical practice – an issue which researchers say needs to be amended.
More than two months after Britain decided to leave the EU, companies reevaluate the state of business and what comes next, specifically for jobs within the industry.
SGS has opened a new Wiesbaden-based facility to serve as its global Center of Excellence for Extractable Studies and Impurities Profiling as customer demand increases.
As stem cell and gene editing technologies become more advanced, researchers are increasingly interested in growing human tissues and organs in animals – but what are the implications of human-animal chimeras?
PharmaJet has inked a multi-year deal with the World Health Organization for its needle-free technology, which uses 80% less vaccine than traditional methods.
Xinxiang Tuoxin Biochemical has received a US FDA warning letter after manufacturing equipment at two API facilities were found to be in a state of disrepair.
Boehringer Ingelheim (BI) and the Duke Clinical Research Institute (DCRI) have expanded their partnership to create the largest patient registry for idiopathic pulmonary fibrosis.
